media – Page 14 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Increasing Market Supply of Influenza Vaccines; 48 Batches of Quadrivalent Influenza Virus Split Vaccine Have Been Released

　　Southern Finance, November 11th – According to CLS (China Lianhe Securities), from Hualan Biological…According to sources, as of now, the company has approved and released influenza vaccines in 2025.54 batches of vaccines have been released, including 48 batches of quadrivalent influenza virus split vaccine. Since October, and especially November, public awareness of influenza vaccination has increased significantly, and the demand orders from disease control centers across the country have increased significantly compared to the same period last year. The company is increasing its market supply of influenza vaccines and will expedite the transportation of vaccines nationwide through cold chain systems after receiving orders from disease control centers across the country to meet the vaccination demand. https://finance.eastmoney.com/a/202511113561078126.html
- Source: drugdu
- 132
- November 12, 2025
Bohui’s innovative freeze-dried Haemophilus influenzae type b conjugate vaccine clinical trial approved

　　On November 11th, Bohui Innovation(300318) issued an announcement stating that its controlling subsidiary, Langfang Bohui, and Baihui Biotechnology jointly applied for the development of freeze-dried influenza B virus.The Haemophilus influenzae conjugate vaccine has received a Drug Clinical Trial Approval Notice from the National Medical Products Administration, agreeing to conduct clinical trials. This vaccine is intended to prevent invasive infections caused by Haemophilus influenzae type b . The relevant application number is CXSL2500616, and the notification number is 2025LP02755. 　　The announcement states that drug development is characterized by high investment, high risk, and long cycles, and carries risks such as clinical trial results falling short of expectations and failure to obtain approval from relevant authorities. This receipt of the “Drug Clinical Trial Approval Notice” is considered a milestone in the development process and is not expected to have a significant impact on the company’s recent performance. 　　In the first three quarters ...
- Source: drugdu
- 68
- November 12, 2025
What diet do people with type 2 diabetes really want? Study reveals flexibility beats strict meal plans

British adults with diabetes overwhelmingly favor simple, adaptable eating patterns over rigid low-calorie meal replacements, highlighting that personal choice may be key to long-term adherence and better health outcomes. In a recent article published in the Journal of Human Nutrition and Dietetics, researchers investigated the dietary approaches preferred by British adults with type 2 diabetes (T2D) and the reasons behind these preferences. They found that most participants preferred moderately calorie-restricted or low-carbohydrate food-based diets, prioritizing ease of following instructions and simplicity as the most important qualities of an adequate diet. Relationship Between Type 2 Diabetes and Dietary Management T2D is closely linked with obesity and overweight, and dietary weight loss remains central to its management. However, many individuals struggle to adhere to prescribed diets due to barriers such as cultural food practices, social routines, and complex diet structures. Current UK Recommendations for Low Energy Diets In the UK, CLEDs, which ...
- Source: drugdu
- 63
- November 12, 2025
Utah researchers uncover microglia as key regulators of anxiety in the brain

Anxiety disorders are some of the most common mental health conditions in America, affecting about one in five people nationwide. But much remains unknown about the roots of anxiety in the brain. Now, research at the University of Utah has identified two surprising groups of brain cells in mice that act as “accelerators” and “brakes” for anxiety. Unexpectedly, the brain cells that regulate anxiety aren’t neurons, the cells that link together to make circuits and pass signals over long distances in the body. Instead, a kind of immune cell called microglia appears to fundamentally regulate whether mice are anxious or not. One group of microglia spurs anxiety responses; the other group tamps them down. “This is a paradigm shift,” says Donn Van Deren, PhD, postdoctoral research fellow at the University of Pennsylvania, who did the research as a postdoctoral research fellow in human genetics at University of Utah Health. “It ...
- Source: drugdu
- 84
- November 12, 2025
【EXPERT Q&A】How to apply for a business license for Class I medical devices?

Drugdu.com expert’s response: Class I medical devices do not require a license for business operations, but if production or specific sales activities are involved, a filing certificate is required. The specific application process is as follows: I. Filing Requirements for Business Operations of Class I Medical Devices Situations Requiring No License or Filing If an enterprise is solely engaged in the sales of Class I medical devices (without involvement in production), it only needs to explicitly include “sales of Class I medical devices” in its business scope on the business license, without the need for additional licenses or filings. Situations Requiring Filing Product Filing: If an enterprise sells self-produced Class I medical devices, it needs to submit filing materials to the local municipal drug regulatory authority (drug administration bureau) before the product is marketed, in order to obtain a “Filing Certificate for Class I Medical Devices”. Production Filing: If an ...
- Source: drugdu
- 72
- November 12, 2025
Phase II Clinical Trial Approved for 9MW3811 Injection in Pathological Scarring

On November 10, Maiwei Biotechnology (688062) issued an announcement stating that the company recently received the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration, which approved the application for Phase II clinical trial of 9MW3811 injection for the indication of pathological scars. The clinical trial notification number for this drug is 2025LP02967. The approval conclusion shows that it meets the relevant requirements for drug registration and allows clinical trials to be conducted. 9MW3811 is a humanized monoclonal antibody targeting human IL-11 independently developed by the company. It has high target affinity and signal blocking ability and is expected to demonstrate efficacy in various diseases such as pathological scars and pulmonary fibrosis. The company plans to launch its Phase II clinical trial for pathological scars by the end of 2025 and has entered into an exclusive licensing agreement with CALICO LIFE SCIENCES LLC. CALICO has already paid ...
- Source: drugdu
- 95
- November 11, 2025
Gan & Lee Pharmaceuticals and Hillhouse Capital have reached a strategic cooperation agreement to optimize resource allocation and explore cooperation opportunities.

Shanghai Securities News China Securities(Reporter Zhang Xue) On November 10, Gan & Lee Pharmaceuticals…The company announced the transfer of its controlling stake in its wholly-owned subsidiary, GanGan Medical Technology Jiangsu Co., Ltd. (hereinafter referred to as “GanGan Jiangsu”), to Hillhouse Capital. Founded in 2017, GanGan Jiangsu is an innovation-driven medical technology company specializing in the research and development and production of high-quality drug delivery devices. Leveraging its strong pharmaceutical background and rigorous quality system, the company has established a comprehensive quality management and regulatory compliance system that meets international standards. Its products have obtained certifications from the U.S. Food and Drug Administration (FDA) and the European Union’s CE MDR (European Union Medical Device Registration System).(Regulations) certification. As the transferee, Hillhouse Capital has long focused on investments in the healthcare sector, possessing comprehensive industry chain insights and resource integration capabilities. Leveraging Hillhouse’s extensive experience in healthcare industry operations and value enhancement, ...
- Source: drugdu
- 89
- November 11, 2025
Sinovac Biotech’s GB12 project has been included in Shenzhen’s strategic emerging industries support plan.

Shanghai Securities News China Securities(Reporter Zhao Binbin) On November 10, this reporter learned from Sinovac Biotech…It has been learned that the innovative drug developed by the company’s wholly-owned subsidiary, Shenzhen Sinovac Biotech Co., Ltd.The GB12 project, “Key Technology Breakthrough for AI-Generated IL-4R/IL-31 Bispecific Antibody Innovative Drugs ,” has been included in the list of projects proposed for funding under the first batch of strategic emerging industries support plans of the Shenzhen Development and Reform Commission in 2025. This project aims to develop a bispecific antibody drug for atopic dermatitis (AD). The drug targets both the IL-4R and IL-31 pathways, targeting both inflammation and itching simultaneously. The project plans to submit new drug clinical trial applications in both China and the United States in the future. https://finance.eastmoney.com/a/202511103560094614.html
- Source: drugdu
- 82
- November 11, 2025
CanSino Biologics and Panru Biotech sign licensing agreement to expand the application prospects of the three-component LNP delivery system

Shanghai Securities News China Securities(News from Nian Yue, reporter Zhang Xue) On the 10th, this reporter learned from CanSino Biologics…It has been learned that CanSino Biologics (Shanghai) Co., Ltd., a subsidiary of the company, recently signed a licensing agreement with Panru Biotechnology (Tianjin) Co., Ltd. (“Panru Biotechnology”), licensing its independently developed novel three-component lipid nanoparticle delivery system (ISL-3C-LNP) to Panru Biotechnology to expand its application prospects. CanSino stated that this licensing cooperation marks another important milestone for the company in the field of mRNA delivery technology, and will bring in more than 100 million yuan in revenue in the future, including upfront payments and milestone payments. 　　According to the agreement, Panru Biotech, upon obtaining authorization, can use ISL-3C-LNP as the core LNP lipid for the global research, development, production, and commercialization of its therapeutic prostate cancer mRNA vaccine (PRBT001 injection). It is understood that PRBT001 injection possesses completely independent intellectual ...
- Source: drugdu
- 93
- November 11, 2025
Influenza vaccine components are updated annually to match seasonal epidemic strains

At present, the vaccine compatibility of the H3N2 subtype influenza virus has further improved compared to previous years, and the compatibility of the H1N1 and B influenza viruses is even higher. ”On November 10th, at a press conference held by the National Bureau of Disease Control and Prevention, Wang Dayan, a researcher at the Institute of Viral Disease Control and Prevention of the Chinese Center for Disease Control and Prevention, answered a question from a Science and Technology Daily reporter about the preventive effect of influenza vaccines, stating that the proportion of epidemic strains with antigenicity similar to vaccine strains exceeded 95%. In response to the misconception among a small portion of the public that the flu virus is constantly mutating and cannot be prevented even with vaccination, Wang Dayan made it clear that although the flu virus is prone to mutation, the flu vaccine will be updated annually to ...
- Source: drugdu
- 93
- November 11, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.